Intelligence · Clinical Pipeline
TG THERAPEUTICS Pipeline
All ClinicalTrials.gov programs at TG THERAPEUTICS — phase, modality, and trial IDs.
- Programs
- 13
Quick answer
TG THERAPEUTICS has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Acalabrutinib
TG THERAPEUTICS, INC.
Chronic Lymphocytic Leukemia
1 trial -
Pembrolizumab
TG THERAPEUTICS, INC.
Hodgkin's Lymphoma
1 trial -
TGR-1202
TG THERAPEUTICS, INC.
Chronic Lymphocytic Leukemia
1 trial -
TGR-1202
TG THERAPEUTICS, INC.
Follicular Lymphoma
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
Relapsing Remitting Multiple Sclerosis
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
multiple sclerosis
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
Autoimmune Disorders
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
Follicular Lymphoma
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
Non-Hodgkins Lymphoma
2 trials -
Umbralisib
TG THERAPEUTICS, INC.
Chronic Lymphocytic Leukemia
4 trials -
Umbralisib
TG THERAPEUTICS, INC.
Lymphoma
1 trial -
Umbralisib
TG THERAPEUTICS, INC.
Marginal Zone Lymphoma
1 trial -
Venetoclax
TG THERAPEUTICS, INC.
Chronic Lymphocytic Leukemia
1 trial
Frequently asked questions
How many pipeline programs does TG THERAPEUTICS have?
13 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs